CAR T-cell therapy has transformed the treatment of blood cancers—but can it do the same for solid tumors?
This concise presentation explores the evolution of CAR T-cell therapy, tracing its breakthrough successes in hematologic malignancies and the complex scientific barriers limiting its effectiveness in solid tumors. It highlights key clinical milestones, explains the biological challenges researchers face today, and examines next-generation innovations shaping the future of cancer immunotherapy. A clear, forward-looking resource for anyone interested in where cellular cancer treatments are headed next.
Maurizio Chiriva Internati (DBSc, PhDs) is a cancer immunologist and biotech entrepreneur with 20+ years in immuno-oncology. Co-founder and former CEO of Kiromic BioPharma (NASDAQ: KRBP), he has led AI-driven target discovery and translational programs, and has served on faculty at MD Anderson and Texas Tech.